🇺🇸 FDA
Pipeline program

Setmelanotide

RM-493-022

Phase 3 small_molecule active

Quick answer

Setmelanotide for Obesity Associated With Defects in Leptin-melanocortin Pathway is a Phase 3 program (small_molecule) at RHYTHM PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
RHYTHM PHARMACEUTICALS, INC.
Indication
Obesity Associated With Defects in Leptin-melanocortin Pathway
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials